Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London afternoon: ECB inaction deflates market

Thu, 02nd Dec 2010 14:28

The absence of any mention of plans to launch a bond purchase in the European Central Bank (ECB) press conference this afternoon has taken some of the glow off equities. "We expect the governments to follow what they are committed to, they all have their adjustment and stabilisation programmes," ECB President Jean-Claude Trichet said at the press conference in Frankfurt.Big company news today has mostly been well received, which has helped alleviate the disappointment regarding the ECB's inaction.TUI Travel has been the best performer throughout the day after it increased underlying pre-tax profit by 4% to £337m during the year to September. Revenue fell 2% to £13.5bn. The increase in profit was driven by integration synergies, the recovery of scheduled flying losses in Germany and the strategic venture in Canada, partially offset by weaker trading. TUI's peer Thomas Cook is in demand after falling yesterday on the back of its numbers. The UK & Irish operations of Kingfisher were a drag on sales growth in the third quarter, as the DIY retailer reported an 8.2% year on year increase in retail profits. Sales in UK & Ireland fell 3.8% and dropped 4.2% like for like. "We enter our fourth quarter in good shape," said boss Ian Cheshire.The initial mineral resource at African Barrick Gold's North Mara project in Tanzania indicates the potential to develop a "substantial underground" operation.Drugs colossus Glaxo is a bit off colour after a federal advisory panel in the US said drugs currently being used to treat enlarged prostates weren't suitable for use as treatments to prevent prostate cancer. That was a knock-back for Glaxo, which is seeking approval from the US Food and Drug Administration to market its Avodart drugs for that very purpose.Barclays is getting rid of several hundred wealthy investment bankers following a big drop in revenues at its "casino" arm.Elsewhere in banking there was tabloid anger at the FSA's decision to exonerate Sir Fred Goodwin, the former chief executive of Royal Bank of Scotland, of accusations of fraud. Turns out "Fred the Shred" and fellow former senior executives of the fallen banking titan were just guilty of making "bad decisions".Investors are raising a glass to pub group and brewer Marston's after it posted a rise in profits despite tough trading in the year to October 2, helped by its shift towards food-oriented pubs. The company, which operates centrally managed pubs such as the Pitcher and Piano chain as well as leasing premises to landlords, saw revenues climb by 0.9% from the previous year, with pre-tax profits climbing to £73.5m from £70.3m.Elsewhere in the drinks industry, soft drinks group Britvic has gone sour even though full-year profits were higher as sales continued fizzing in spite of subdued economic conditions. The company, which sells its own brand of juice and distributes Pepsi in Britain, posted a pre-tax profit of £109.1m in the 53 weeks to October 3, up from £104.6m the previous year. Revenues, excluding the impact of the acquisition of Britvic France in May, were up to £1,138.6m from £1,121.1m. Infrastructure specialist Balfour Beatty has reached financial close for the £55m Derby City Building Schools for the Future (BSF) programme. The Derby City BSF Partnership project involves the delivery of a capital investment programme for schools in Derby in partnership with Derby City Council.Telecoms firm Cable & Wireless Communications (CWC) is set to acquire a controlling interest in the Bahamas Telecommunications Company (BTC). CWC will buy a 51% interest in the government-owned BTC, subject to necessary consents and other regulatory clearances, for $210m. BTC is being acquired with $15m of net cash on the books.Desire Petroleum has gushed ahead after saying it has found oil in the treacherous waters off the Falkland Islands, according to preliminary data collected from Rachel North exploration well 14/15-2. The well in the North Falkland Basin reached a total depth of 3,052 metres, and drilling data and other tests indicate the well encountered a 349 metre gross interval of sands and shales with hydrocarbons, of which 57 metres is net pay in multiple zones. Meanwhile, JJB Sports slumps after saying it is likely to breach its banking covenants as sales continue to fall short of expectations at the sports shop chain. Trading conditions have been "extremely challenging" since it last updated the market early last month and the company thinks this has been exacerbated by the current bad weather.IT supplies and services company Datatec is to buy US network systems firm Network Infrastructure Corporation for an undisclosed sum. Fellow techie firm, Florida-based wireless communications firm XG Technology surged on news that MB Technology Holdings, which already owns almost 40% of the XG, is considering pumping an extra $10m into the company.Postman Pat company Character Group delivered a pleasing set of full year results, returning to the black with a pre-tax profit of £7.55mcompared with a loss of £2.17m a year earlier.Gold miner Solomon Gold said that results from recent drilling at various Queensland prospects continue to support the targeted resource definition of one million ounces of gold equivalent.The share price of motion capture specialist OMG moved to a 52-week high after its "best ever year". Both sales and profits were ahead of expectations.Aurum Mining fell over 80% as the shares began trading without the right to enjoy the proposed return of capital to shareholders. Investors will be receiving cheques for almost £7.8m, leaving the company with a likely cash pile of £840,000, worth 1.6p a share, at the end of December.
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.